Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituximab, gemcitabine, cisplatin, and dexamethasone)

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Carboplatin / therapeutic use
• Cisplatin / therapeutic use
• Deoxycytidine / analogs & derivatives
• Dexamethasone / adverse effects
• Gemcitabine
• Humans
• Lymphoma, Follicular* / diagnosis
• Lymphoma, Follicular* / drug therapy
• Lymphoma, Large B-Cell, Diffuse* / diagnosis
• Lymphoma, Large B-Cell, Diffuse* / drug therapy
• Lymphoma, Large B-Cell, Diffuse* / pathology
• Lymphoma, Non-Hodgkin* / drug therapy
• Neoplasm Recurrence, Local / drug therapy
• Neoplasm Recurrence, Local / pathology
• Retrospective Studies
• Rituximab / adverse effects
• Salvage Therapy